» Articles » PMID: 38675100

Polymeric Nanoparticles Enable MRNA Transfection and Its Translation in Intervertebral Disc and Human Joint Cells, Except for M1 Macrophages

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Apr 27
PMID 38675100
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic lower back pain caused by intervertebral disc degeneration and osteoarthritis (OA) are highly prevalent chronic diseases. Although pain management and surgery can alleviate symptoms, no disease-modifying treatments are available. mRNA delivery could halt inflammation and degeneration and induce regeneration by overexpressing anti-inflammatory cytokines or growth factors involved in cartilage regeneration. Here, we investigated poly(amidoamine)-based polymeric nanoparticles to deliver mRNA to human joint and intervertebral disc cells. Human OA chondrocytes, human nucleus pulposus (NP) cells, human annulus fibrosus (AF) cells, fibroblast-like synoviocytes (FLS) and M1-like macrophages were cultured and transfected with uncoated or PGA-PEG-coated nanoparticles loaded with EGFP-encoding mRNA. Cell viability and transfection efficiency were analyzed for all cell types. Nanoparticle internalization was investigated in FLS and M1-like macrophages. No significant decrease in cell viability was observed in most conditions. Only macrophages showed a dose-dependent reduction of viability. Transfection with either nanoparticle version resulted in EGFP expression in NP cells, AF cells, OA chondrocytes and FLS. Macrophages showed internalization of nanoparticles by particle-cell co-localization, but no detectable expression of EGFP. Taken together, our data show that poly (amidoamine)-based nanoparticles can be used for mRNA delivery into cells of the human joint and intervertebral disc, indicating its potential future use as an mRNA delivery system in OA and IVDD, except for macrophages.

Citing Articles

Nanotechnology-Enhanced Pharmacotherapy for Intervertebral Disc Degeneration Treatment.

Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L Int J Nanomedicine. 2025; 19:14043-14058.

PMID: 39742093 PMC: 11687283. DOI: 10.2147/IJN.S500364.

References
1.
Bedingfield S, Colazo J, Yu F, Liu D, Jackson M, Himmel L . Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nat Biomed Eng. 2021; 5(9):1069-1083. PMC: 8497446. DOI: 10.1038/s41551-021-00780-3. View

2.
Pontes A, van der Wal S, Ranamalla S, Roelofs K, Tomuta I, Creemers L . Cell uptake and intracellular trafficking of bioreducible poly(amidoamine) nanoparticles for efficient mRNA translation in chondrocytes. Front Bioeng Biotechnol. 2023; 11:1290871. PMC: 10668025. DOI: 10.3389/fbioe.2023.1290871. View

3.
Sturm L, Schwemberger B, Menzel U, Hackel S, Albers C, Plank C . In Vitro Evaluation of a Nanoparticle-Based mRNA Delivery System for Cells in the Joint. Biomedicines. 2021; 9(7). PMC: 8301349. DOI: 10.3390/biomedicines9070794. View

4.
Sarzi-Puttini P, Cimmino M, Scarpa R, Caporali R, Parazzini F, Zaninelli A . Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum. 2005; 35(1 Suppl 1):1-10. DOI: 10.1016/j.semarthrit.2005.01.013. View

5.
Lin C, Zhong Z, Lok M, Jiang X, Hennink W, Feijen J . Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: synthesis and in vitro gene transfer properties. J Control Release. 2006; 116(2):130-7. DOI: 10.1016/j.jconrel.2006.09.009. View